Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates.
about
Parainfluenza virusesChimeric bovine respiratory syncytial virus with attachment and fusion glycoproteins replaced by bovine parainfluenza virus type 3 hemagglutinin-neuraminidase and fusion proteinsRecombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.A chimeric human-bovine parainfluenza virus type 3 expressing measles virus hemagglutinin is attenuated for replication but is still immunogenic in rhesus monkeys.Progress in the development of human parainfluenza virus vaccinesChimeric recombinant human metapneumoviruses with the nucleoprotein or phosphoprotein open reading frame replaced by that of avian metapneumovirus exhibit improved growth in vitro and attenuation in vivoMucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backboneRecombinant wild-type and edmonston strain measles viruses bearing heterologous H proteins: role of H protein in cell fusion and host cell specificityMore antibody with less antigen: can immunogenicity of attenuated live virus vaccines be improved?The two major human metapneumovirus genetic lineages are highly related antigenically, and the fusion (F) protein is a major contributor to this antigenic relatednessThe genome length of human parainfluenza virus type 2 follows the rule of six, and recombinant viruses recovered from non-polyhexameric-length antigenomic cDNAs contain a biased distribution of correcting mutations.Determinants of the host range restriction of replication of bovine parainfluenza virus type 3 in rhesus monkeys are polygenic.Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics.Nonsegmented negative-strand viruses as vaccine vectors.Roles of the fusion and hemagglutinin-neuraminidase proteins in replication, tropism, and pathogenicity of avian paramyxoviruses.Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.The M, F and HN genes of genotype VIId Newcastle disease virus are associated with the severe pathological changes in the spleen of chickens.New generation live vaccines against human respiratory syncytial virus designed by reverse genetics.Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young childrenContributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity.Parainfluenza Virus 3 Blocks Antiviral Mediators Downstream of the Interferon Lambda Receptor by Modulating Stat1 PhosphorylationInfluence of antigen insertion site and vector dose on immunogenicity and protective capacity in Sendai virus-based human parainfluenza virus type 3 vaccines.Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV.Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children.Chimeric bovine/human parainfluenza virus type 3 expressing respiratory syncytial virus (RSV) F glycoprotein: effect of insert position on expression, replication, immunogenicity, stability, and protection against RSV infection.Efficient and Robust Paramyxoviridae Reverse Genetics Systems.Recent developments with live-attenuated recombinant paramyxovirus vaccines.RNA-based viral vectors.Reverse genetics of Mononegavirales: How they work, new vaccines, and new cancer therapeuticsImproved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate.Zoonotic Potential of Emerging Paramyxoviruses: Knowns and Unknowns.Long-term protection in hamsters against human parainfluenza virus type 3 following mucosal or combinations of mucosal and systemic immunizations with chimeric alphavirus-based replicon particles.Vaccines for the Paramyxoviruses and Pneumoviruses: Successes, Candidates, and Hurdles.Progress in respiratory virus vaccine development
P2860
Q24682952-3D830901-2CD8-418C-9A89-61F008BF277AQ30708312-56097750-7DDD-48CB-82D8-AED5D4544A97Q33840469-919AAACD-8489-4093-AA33-EB9E99BE1759Q33848343-80B2C401-E015-49E4-8C28-F316E6A5D669Q34209872-F2133239-BC1A-4D4F-A5A2-ECF4495D1521Q34228628-3ADFEB1A-A794-498F-B2B7-D5FCEC40658BQ34328895-D2EA2FA6-6210-4CD1-86E2-8263AFFDD1F8Q34338440-209E5FC1-4A6A-470E-B1C1-021414B0C644Q34430473-94DAB2C5-9BDE-4BB6-8A5B-78A18E7999D6Q34439107-D4ECB664-F0CF-4F24-937E-D4C8187BAACBQ34462261-64874409-FBCF-4C34-8B4F-F19F64E66C3EQ34465213-6D344315-BC87-4CC2-AC36-B583C39FD021Q34717853-BEEBB6B1-C778-45F8-8831-FA16A090E37DQ35139219-1AC70A3C-B90B-40B8-AE64-B78508F3C858Q35192881-880EE1FE-827C-4335-85DB-82A6A6808BA0Q35973617-90308DC7-04DC-4575-B68C-4D2D366DA6C3Q36023225-15C06DC2-85A2-42E8-ADA7-F421F2C1F964Q36237057-D8FBED0D-6421-42D7-8E79-4B4DB8164C53Q36433111-8FEF7D08-7DC1-400F-852F-CEAE6217913FQ36449078-BD1E12E1-3591-4DD7-A552-0C8FDD8F82EEQ36736583-A4F52FBF-4FF2-4649-A98C-391E7140BF20Q36827280-3E474485-701F-440E-987A-D2DCA020892FQ37348134-4E73C633-734E-470A-B5E8-4D294422BDF7Q37470206-085976BF-69B4-4813-B22D-6877D3E64BC3Q37713874-B9CF34D1-F632-433D-B697-147C051D46ADQ37727631-32861791-886A-4628-9BFF-3A087940EC66Q38008607-F50675ED-0351-43A5-9630-76447A0A9A11Q38266413-F7498FC5-91A0-4E56-BD16-DAAC1B304FCBQ38363535-F8CEA584-A7B3-4D41-8819-586DE9694B51Q40187606-F9DF54DA-CCA1-4610-954C-58060672BBAAQ40231964-67FDAAED-9C7C-4F3F-84FA-971D6108F8D2Q45399630-E9ED7B93-6F0D-4014-AB2A-1A87A53FC478Q47555408-EF0AC34B-FA34-4D9A-B783-D0BD2030E2E4Q56894869-B3D4DC55-E8D8-430D-85F2-BBACC286345D
P2860
Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates.
description
2000 nî lūn-bûn
@nan
2000 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Bovine parainfluenza virus typ ...... lication of BPIV3 in primates.
@ast
Bovine parainfluenza virus typ ...... lication of BPIV3 in primates.
@en
type
label
Bovine parainfluenza virus typ ...... lication of BPIV3 in primates.
@ast
Bovine parainfluenza virus typ ...... lication of BPIV3 in primates.
@en
prefLabel
Bovine parainfluenza virus typ ...... lication of BPIV3 in primates.
@ast
Bovine parainfluenza virus typ ...... lication of BPIV3 in primates.
@en
P2093
P2860
P1433
P1476
Bovine parainfluenza virus typ ...... lication of BPIV3 in primates.
@en
P2093
Collins PL
McAuliffe JM
Schmidt AC
Skiadopoulos MH
P2860
P304
P356
10.1128/JVI.74.19.8922-8929.2000
P577
2000-10-01T00:00:00Z